Business Context and Reporting Period
Company: CorMedix Inc. (CRMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: CorMedix is a biopharmaceutical company focused on commercializing DefenCath, an FDA-approved antimicrobial catheter lock solution for hemodialysis patients. The product launched commercially in the U.S. inpatient setting in April 2024 and the outpatient setting in July 2024.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net Sales (Revenue) | $39.7 million | $78.8 million |
| Gross Profit | $37.9 million (95.3% margin) | $75.4 million (95.6% margin) |
| Net Income | $19.8 million | $40.5 million |
| Diluted EPS | $0.28 | $0.58 |
| Operating Cash Flow | N/A | $49.7 million (Six Months) |
| Cash & Short-Term Investments | $190.7 million (as of June 30, 2025) | N/A |
| Total Liabilities | $32.0 million | N/A |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 4,829% for the quarter and 9,678% year-to-date compared to 2024, driven by the commercial launch of DefenCath. Prior year revenue was negligible ($0.8 million).
- Profitability Turnaround: The company transitioned from a net loss of $14.2 million (Q2 2024) to a net income of $19.8 million (Q2 2025). Year-to-date results shifted from a $28.6 million loss in 2024 to a $40.5 million profit in 2025.
- Expense Trends:
- R&D: Increased 275% QoQ and 279% YoY due to ongoing clinical studies.
- Selling & Marketing: Decreased 14% QoQ and 21% YoY as pre-launch marketing costs from 2024 subsided.
- G&A: Increased 25% QoQ and 18% YoY, largely driven by non-cash stock-based compensation.
- Liquidity: Cash and cash equivalents grew from $40.7 million (Dec 31, 2024) to $159.3 million (June 30, 2025), bolstered by a $82.4 million public offering in June 2025.
Guidance, Outlook, and Material Events
Subsequent Events (Post-June 30, 2025)
- Acquisition of Melinta Therapeutics: On August 7, 2025, CorMedix entered into a merger agreement to acquire Melinta. The deal includes $260 million in cash and $40 million in stock, expected to close in September 2025. Contingent payments up to $25 million are tied to FDA approvals for Melinta's product REZZAYO.
- Convertible Notes Offering: On August 6, 2025, the company agreed to issue $150 million in 4.00% convertible senior notes due 2030 to fund the Melinta acquisition.
- Tax Legislation: The "One Big Beautiful Bill Act" signed July 4, 2025, restores immediate expensing for R&D and 100% bonus depreciation, expected to favorably impact future tax rates.
Risks and Contingencies
- Legal Proceedings: Ongoing securities class action and derivative litigation regarding prior NDA submissions and FDA communications. The court denied the company's motion to dismiss in June 2025, though the opinion was withdrawn in July 2025 pending a new order.
- Accounting Estimates: A change in estimate regarding Medicaid utilization rates negatively impacted Q2 net income by $2.0 million and YTD net income by $1.7 million.
- Supply Chain: Reliance on third-party manufacturers in Europe for DefenCath; potential exposure to new EU-U.S. tariffs on pharmaceuticals announced in July 2025.
Investor Verification Checklist
- Merger Closing: Verify the satisfaction of HSR clearance and other conditions for the Melinta acquisition expected in September 2025.
- Revenue Sustainability: Monitor the impact of the Medicaid utilization rate estimate change on future revenue recognition and gross-to-net deductions.
- Capital Structure: Confirm the issuance of the $150 million convertible notes and the dilution impact of the $40 million equity component of the Melinta deal.
- Legal Exposure: Track the status of the securities litigation following the court's withdrawal of its June 2025 opinion.
- Supply Chain Costs: Assess the financial impact of potential 15% tariffs on pharmaceutical imports from the EU on DefenCath margins.